Blinatumomab
Based on 3 publication(s) in Google Scholar
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.32%
- CAS No.: 853426-35-4
- 분자량:54.09 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Blinatumomab
More-
Others
Biological Activity
제품 설명
Isotype
(scFv-kappa-heavy)-(scFv-heavy-kappa)
Species Reactivity
Human
IC50 & Target
CD19 & CD3E
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:leukemic nonobese diabetic SCID mouse model (20 days old)[2]
-
Dosage:0.01-1 μg
-
Administration:Intravenous injection (i.v.), once daily for 5 days
-
Result:Caused none of the animals developed detectable tumors and survived inoculation of NALM-6 cells at cumulative doses of 5 or 0.5 μg for the entire observation period of 76 days. Cumulative doses of 0.05 and 0.005 μg were not effective in preventing tumor growth.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
(scFv-kappa-heavy)-(scFv-heavy-kappa)
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded Blinatumomab on CM5 Chip, can bind CD19 Protein, Human (CHO, Fc, HY-P7333) with an affinity constant of 11.02E-9 M as determined in SPR assay. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Blinatumomab (HY-P9963). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 853426-35-4
-
Appearance Liquid
-
분자량 54.09 kDa
-
Color Colorless to light yellow
-
SMILES
[Blinatumomab]
-
Synonyms
bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement. [Abstract]2024 Jun 18;5(6):101590. PMID: 38843844
Blinatumomab purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Jun 18;5(6):101590. [Abstract]
Histogram of the percentage of conjugated cells when 2 × 105 Dye 670-stained NY-ESO-1157-165-primed HLA-A∗0201-Raji cells were cocultured 1 h with mixed 2 × 104 CFSE-stained 1G4-PD-1-Jurkat cells and 2 × 104 Dye 450-stained PD-1-Jurkat cells. The concentration of αPD-1-(iRGD)2 was 10 μg/mL, while Blinatumomab (1 μg/mL; 1 h) .
-
bioRxiv
Single injection of modified self-amplifying RNA encoding a CD19 bispecific T cell engager mediates long-term malignant B cell clearance. [Abstract]2026 Apr 19:2026.04.18.719371. PMID: 42039561 -
순도&문서
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kantarjian H, et, al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376(9):836-847. [Content Brief]
[2]. Dreier T, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol. 2003 Apr 15;170(8):4397-402. [Content Brief]
[3]. Hoffman LM, et al. Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications. Front Oncol. 2014 Mar 31;4:63. [Content Brief]
[4]. Zhang R, et al. The establishment and application of CD3E humanized mice in immunotherapy[J]. Experimental Animals, 2022, 71(4): 442-450. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)